The allocation of BSPCEs (Bons de Souscription de Parts de Créateurs d’Entreprise) to independent board directors: a small revolution for joint stock companies, a real breakthrough for the biotech world

Written By

sofia el biyed Module
Sofia El Biyed

Associate
France

I advise our clients on a broad range of corporate matters, with a focus on private equity transactions and mergers and acquisitions.

emmanuelle porte Module
Emmanuelle Porte

Partner
France

As a Corporate partner in the Bird & Bird Life Sciences team in Paris, I mainly advise innovative companies financed by venture capital, in particular biotech/medtech, digital health, and wellness companies.

Biotech and medtech companies operate in an international environment where the composition of their governance bodies is a key criterion of credibility. As said by the President of France Biotech, Maryvonne Hiance: “bringing renowned scientists or entrepreneurs to their boards of directors is not a luxury, it is an essential tool of attractiveness.”

As part of the recent PACTE law of 22 May 2019, the French legislator has finally addressed the crucial need of biotech and medtech companies to be able to properly compensate independent board directors – most often very popular people of high international scientific background – by allowing companies to issue tax favorable « stock-options » (BSCPE) to independent board directors.

Until now, BSPCEs could only be granted to employees or corporate officers of joint stock companies (sociétés par actions) created less than 15 years ago and if listed, with a market capitalisation that does not exceed 150 million euros.

View the full article in our BioTalk blog.

Latest insights

More Insights
Curiosity line green background

Navigating the Complex Landscape of Merger Control and Foreign Direct Investment in Life Sciences in the EU and UK

Oct 01 2024

Read More
Curiosity line blue background

A Clearly Drafted Discretionary Bonus Clause Upholds Employer’s Right to Withhold Bonuses

Sep 20 2024

Read More
Magnifying Glass on green background

Challenging Decisions Under The Procurement Act 2023 – The Changing Landscape

Sep 19 2024

Read More